Bempedoic acid (BA, ETC1002) is an ACLY inhibitor that has shown therapeutic potential for fatty liver disease by inhibiting the hepatic PXR-SLC13A5/ACLY signaling axis, and it may serve as a supplementary therapy for patients who are intolerant to statins [152]. This evidence concerns the gene ACLY and fatty liver disease.